PaNeX: Partial Nephrectomy Under Xenon (PaNeX)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01839084 |
Recruitment Status :
Completed
First Posted : April 24, 2013
Last Update Posted : February 18, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Renal Function After Partial Nephrectomy | Drug: Xenon Drug: Isoflurane | Phase 3 |
A partial nephrectomy is accompanied by ischemia time, followed by reperfusion. This frequently leads to a kidney injury of the remained tissue and decrease of the renal function after surgery. As it was shown that Xenon has protective properties against ischemia/reperfusion injury, the investigators hypothesize that Xenon application during partial nephrectomy leads to a stronger nephroprotection than an anesthesia with Isoflurane.
The study will be conducted by two investigator types: The study enrollment and the post-anesthesia follow-up will be performed by Investigator I who is blinded to the study treatment. Investigator II will only perform general anesthesia for partial nephrectomy and will therefore necessarily be unblinded to the treatment conditions.
Patients will be randomly assigned to one of the following study groups. Group 1 (Xenon) will receive Xenon for maintenance of balanced anesthesia for partial nephrectomy. Group 2 (Isoflurane) will receive Isoflurane for the same surgery.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 46 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Impact of Xenon-anesthesia on the Renal Function After Partial Nephrectomy - PaNeX: Partial Nephrectomy Under Xenon:a Pilot Study |
Study Start Date : | July 2013 |
Actual Primary Completion Date : | February 2016 |
Actual Study Completion Date : | February 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Xenon
Gaseous anesthetic, dosage: 60% (v/v) in 40% oxygen, continuous application during surgery
|
Drug: Xenon
general anaesthesia with xenon 60% in oxygen (FiO2=0.4)
Other Name: Lenoxe |
Active Comparator: Isoflurane
Inhalative anesthetic, dosage: 1.2% (v/v) in 40% oxygen/medical air , continuous application during surgery
|
Drug: Isoflurane
general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
Other Name: Forene |
- Evaluation of the impact of xenon-anesthesia on the renal function after partial nephrectomy, compared to an isoflurane-anesthesia. [ Time Frame: Within the first 7 postoperative days ]Evaluation of the maximum decrease of glomerular filtration rate (GFR) within 7 days after partial nephrectomy surgery. Maximum decrease will be assessed by the difference between the baseline value of GFR and the minimum value of GFR after surgery.
- Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: Intraoperatively ]Ischaemia time
- Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: Intraoperatively ]Duration of xenon/isoflurane exposition before and after the kidney ischemia time.
- Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: Intraoperatively until discharge from hospital ]Tumor size and histology, if applicable detection of hypoxia-inducible factor 1α (HIF-1α) in healthy resection border tissue
- Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: Intraoperatively and within the first 7 postoperative days ]Measurement of macrophage migration inhibitory factor (MIF) in serum
- Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: preaoperativ and Within the first 7 postoperative days ]Course of GFR determined with the Cystatin C value in serum
- Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: preaoperativ and Within the first 7 postoperative days ]Course of creatinine value in serum
- Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: Within the first 7 postoperative days ]Urine output within the first 48houres after surgery
- Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: Within the first 7 postoperative days ]If applicable determination of kidney injury molecule-1 (KIM-1)or neutrophil gelatinase-associated lipocalin (NGAL)
- Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: Within the first 7 postoperative days ]Determination of acute kidney failure according to the AKIN classification
- Safety criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: intraoperative ]Doses and concentration of study treatments
- Safety criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: intraoperative and within the first 7 postoperative days ]The peri-anaesthetic respiratory profile
- Safety criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: intraoperative and within the first 7 postoperative days ]The peri-anaesthetic haemodynamic profile
- Safety criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: intraoperative ]Intra-operative blood loss
- Safety criteria for using xenon-anaesthesia during partial nephrectomy. [ Time Frame: intraoperative and within the first 7 postoperative days ]The incidence of adverse event (AE) and serious adverse event (SAE)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients willing and able to complete the requirements of this study
- Patients with renal carcinoma restricted to one kidney
- Patients undergoing partial nephrectomy
- Men and women >= 18 yrs
- Informed consent
Exclusion Criteria:
- Chronic renal failure with a GFR < 60ml/min/1,73m2 body surface area
- American Society of Anesthesiologists (ASA)>III
- Hypersensitivity to the study anaesthetics
- Chronic obstructive pulmonary disease (COPD) GOLD IV
- Acute coronary syndrome during the last 24 hours; haemodynamic instability, requirement of inotropic support
- Severe cardial dysfunction New York Heart Association (NYHA) >III
- Disabling neuropsychiatric disorders
- Increased intracranial pressure
- pregnant or breastfeeding women
- Women of childbearing potential
- Presumed uncooperativeness or legal incapacity
- Lack of informed consent
- Participation in a concomitant trial within the last 30 days

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01839084
Germany | |
Department of Anesthesiology, University Hospital Aachen | |
Aachen, NRW, Germany, 52074 |
Principal Investigator: | Astrid Fahlenkamp, Dr. med. | Department of Anesthesiology, University Hospital Aachen |
Responsible Party: | RWTH Aachen University |
ClinicalTrials.gov Identifier: | NCT01839084 |
Other Study ID Numbers: |
12-051 2012-005698-30 ( EudraCT Number ) |
First Posted: | April 24, 2013 Key Record Dates |
Last Update Posted: | February 18, 2016 |
Last Verified: | February 2016 |
Xenon Isoflurane Anesthetics, Inhalation |
Nephroprotection Partial nephrectomy Xenon versus Isoflurane anesthesia |
Isoflurane Anesthetics, Inhalation Anesthetics, General |
Anesthetics Central Nervous System Depressants Physiological Effects of Drugs |